Skip to main content

Open-Label Placebo Plus Treatment Rationale Effective for PMS

Medically reviewed by Carmen Pope, BPharm. Last updated on March 28, 2025.

By Elana Gotkine HealthDay Reporter

FRIDAY, March 28, 2025 -- Open-label placebo (OLP) provided with a treatment rationale is effective and safe for premenstrual syndrome (PMS), according to a study published online March 25 in BMJ Evidence-Based Medicine.

Antje Frey Nascimento, from the University of Basel in Switzerland, and colleagues conducted a randomized controlled trial involving 150 women aged 18 to 45 years with PMS or premenstrual dysphoric disorder. Participants were randomly assigned to treatment as usual (TAU; 50 women), OLP without treatment rationale (OLP−; 50 women), or OLP with treatment rationale (OLP+; 50 women); OLP consisted of two placebo pills per day for six weeks.

The researchers found that across three menstrual cycles (MC1 to MC3), there was a difference between the groups in symptom intensity and interference. At MC3, mean symptom intensity was lower for OLP+ versus TAU and OLP− (b = −9.97 and −6.10), while no difference was seen between TAU and OLP−. At MC3, mean interference was lower for OLP+ than for TAU or OLP− (b = −1.23 and −1.10), with no difference between TAU and OLP−. There were reports of four nonserious adverse events in OLP− and OLP+ (one and three, respectively). High adherence was seen to the OLP intervention (93.18 ± 18.95 percent), with no between-group difference.

"Considering our results as much as the individual and societal burden of PMS, OLP treatment could serve as an acceptable, efficacious, and safe intervention for PMS," the authors write.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Declining Childhood Vaccination May Increase Risk for Vaccine-Preventable Infections

WEDNESDAY, April 30, 2025 -- Declining childhood vaccination rates may increase outbreaks of eliminated vaccine-preventable infections within the United States, leading to a...

AACR: Incidence-Based Mortality Dropping for Young Women With Breast Cancer

TUESDAY, April 29, 2025 -- Incidence-based mortality (IBM) declined from 2010 to 2020 among women aged 20 to 49 years diagnosed with breast cancer, according to a study presented...

AACR: Nonsurgical Treatment Feasible for Mismatch Repair-Deficient Tumors

TUESDAY, April 29, 2025 -- A neoadjuvant programmed cell death 1 (PD-1) blockade enables nonoperative management among patients with early-stage mismatch repair-deficient (dMMR)...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.